Physician profile
Fazal Rahim
NPI 1811097462
$13,704.18
in general payments reported to CMS, 2019-2025
47 companies · $3,930 in 2025
The $3,930 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,331 · 2020: $771 · 2021: $1,425 · 2022: $1,248 · 2023: $1,276 · 2024: $3,724 · 2025: $3,930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,906 · Education: $23.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,906.00 |
| Education | $23.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,530.80 | 2019-2025 | |
| Csl Behring | $1,187.69 | 2020-2025 | Hizentra |
| Biogen, INC. | $1,033.34 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Ucb, INC. | $923.38 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Eisai INC. | $910.63 | 2023-2025 | |
| Abbvie INC. | $741.93 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $707.61 | 2022-2025 | Xywav |
| Sk Life Science, INC. | $664.58 | 2021-2025 | |
| Lilly USA, LLC | $600.91 | 2019-2025 | Emgality, Amyvid, Reyvow |
| Pfizer INC. | $582.49 | 2023-2025 | |
| Emd Serono, INC. | $566.35 | 2019-2025 | Mavenclad |
| Argenx US, INC. | $506.75 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Avadel Cns Pharmaceuticals, LLC | $436.55 | 2024-2025 | Lumryz |
| Axsome Therapeutics, INC. | $423.37 | 2022-2025 | Sunosi |
| Amgen INC. | $316.36 | 2019-2025 | Uplizna |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fazal Rahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.